Literature DB >> 11065040

Improved patient acceptability with a transdermal drug-in-adhesive oestradiol patch.

Y Lake1, S Pinnock.   

Abstract

The aim of this trial was to assess the relative patient acceptability of two transdermal oestradiol patches used in treatment of oestrogen deficiency in postmenopausal women. Thirty-five hysterectomised postmenopausal women with no previous experience of transdermal oestradiol delivery systems received treatment with either once-weekly drug-in-adhesive (DIA) patches or twice-weekly reservoir patches for 4 weeks, and were then switched to the alternative treatment for a further 4 weeks. At the end of the study, the patients completed a questionnaire to assess their relative preference for a number of characteristics of the 2 transdermal systems and, where possible, their preference for transdermal compared with oral hormone replacement therapy. Thirty-one patients completed the study; four withdrew during treatment with the reservoir patch. The DIA patch was preferred for being 'easiest to remember to apply' by 80% of patients (p < 0.01), 'easiest to open' and 'easiest to apply' by 68% (p = 0.025), and as having 'best cosmetic appearance' by 65% (p = 0.05) and 'best overall skin adhesion' by 61% (p < 0.01). While 10% of patients rated the reservoir patch as 'least irritating to the skin' (p = 0.03), only one patient found this patch 'most comfortable to wear' (p < 0.01). The DIA patch was selected by 87% of patients as their preferred treatment overall (p = 0.001). Ninety-one per cent of 22 responding patients were at least as confident of treatment with transdermal patches as with oral hormone replacement therapy (p = 0.006) and 74 % of 27 responders preferred transdermal to oral treatment (p = 0.004). The DIA patch appears to be more acceptable to patients than the reservoir patch as a transdermal oestradiol delivery system for the treatment of postmenopausal oestrogen deficiency. Characteristics of the DIA patch which may account for improved patient acceptance include ease of remembering once-weekly patch application, improved cosmetic appearance and comfort, and better adhesion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11065040     DOI: 10.1111/j.1479-828x.2000.tb03341.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  5 in total

Review 1.  Transdermal patches: history, development and pharmacology.

Authors:  Michael N Pastore; Yogeshvar N Kalia; Michael Horstmann; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

2.  Transdermal therapy for overactive bladder: present and future.

Authors:  Victor W Nitti
Journal:  Rev Urol       Date:  2003

3.  Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease : ACEPTO study.

Authors:  Carlos Martín de Argila; Julio Ponce; Emilio Márquez; M José Plazas; Jordi Galván; Joan Heras; Joana Porcel
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

4.  Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate.

Authors:  Abdul Ahad; Abdulmohsen A Al-Saleh; Abdullah M Al-Mohizea; Fahad I Al-Jenoobi; Mohammad Raish; Alaa Eldeen B Yassin; Mohd Aftab Alam
Journal:  Saudi Pharm J       Date:  2017-02-02       Impact factor: 4.330

5.  Peeking into the future: Transdermal patches for the delivery of micronutrient supplements.

Authors:  Maria G Grammatikopoulou; Konstantinos Gkiouras; Efthimios Dardiotis; Efterpi Zafiriou; Christina Tsigalou; Dimitrios P Bogdanos
Journal:  Metabol Open       Date:  2021-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.